FDA Approves Risankizumab (Skyrizi) for Crohn ’s Disease FDA Approves Risankizumab (Skyrizi) for Crohn ’s Disease

The approval is the third indication for the anti-interleukin 23 monoclonal antibody after approval for psoriatic arthritis earlier this year and plaque psoriasis in 2019.FDA Approvals
Source: Medscape Gastroenterology Headlines - Category: Gastroenterology Tags: Gastroenterology News Alert Source Type: news